Rivus Pharmaceuticals Inc., a Charlottesville, VA-based clinical-stage biopharmaceutical firm devoted to bettering cardio-metabolic well being, accomplished a $132m Sequence B financing.
The spherical was led by RA Capital Administration with participation from Bain Capital Life Sciences, BB Biotech AG and present buyers Longitude Capital, Medicxi and RxCapital. Along with the funding, Derek DiRocco, associate at RA Capital, new board director.
The corporate intends to make use of the funds for scientific development of lead candidate HU6, a Managed Metabolic Accelerator (CMA) designed to deal with cardio-metabolic illness by addressing weight problems, a major driver of illness.
Led by Allen Cunningham, President and CEO, Rivus Prescribed drugs is a pacesetter in mitochondrial biology devoted to bettering cardio-metabolic well being by advancing a brand new class of medicines, Managed Metabolic Accelerators (CMAs). Its small molecule remedy, HU6, represents a chance to empower sufferers on their journey to well being when going through a broad vary of situations, together with weight problems, coronary heart failure with preserved ejection fraction (HFpEF), sort 2 diabetes, and Nonalcoholic fatty liver illness (NAFLD)/Nonalcoholic steatohepatitis (NASH).
Rivus’ CMAs are designed to soundly harness mitochondrial uncoupling, a pure course of that regulates and dissipates vitality, to selectively scale back fats all through the physique. Earlier this yr, the corporate launched knowledge from a Section 2a metabolic research investigating lead candidate HU6 in overweight contributors. The research supplied proof of idea validation that CMAs have the potential to deal with not solely weight problems, however a spread of cardio-metabolic ailments together with coronary heart failure with preserved ejection fraction (HFpEF), sort 2 diabetes and Nonalcoholic fatty liver illness (NAFLD)/Nonalcoholic steatohepatitis (NASH).